1 **Manuscript title: Loss in the expansion of SARS-CoV-2 specific immunity is a key risk**
2 **factor in fatal patients with COVID-19**

3

4 Qiang Zeng, MD[#], Gang Huang, MD[#], Yong-zhe Li, MD[#], Guoqiang Xu, PhD, Sheng-yong Dong,
5 MD, Tian-yu Zhong, MD, Zong-tao Chen, MD, Yang Xu, MD, PhD^{*}

6 **Authors' name and affiliations:**

7 Chinese PLA General Hospital, Beijing, China (Q. Zeng, S.Y. Dong); Shanghai University of
8 Medicine and Health Sciences, Shanghai, China (G. Huang, Y. Xu); Jiangsu Key Laboratory of
9 Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
10 (G. Xu); First Affiliated Hospital, Gannan Medical University, Ganzhou, China (T.Y. Zhong); The
11 first affiliated Hospital, Army Medical University, Chongqing, China (Z.T. Chen); Department of
12 Laboratory Medicine, Peking Union Medical College Hospital, Beijing, China (Y.Z. Li).

13

14 *** Contact information for the corresponding author:**

15 Yang Xu, MD, PhD, Director
16 Laboratory of Special Diagnosis
17 Shanghai University of Medicine and Health Sciences
18 Shanghai 201318, China
19 E-mail: yxu1627@126.com

20

21

22 **Highlights**

23

24 ● **The immune system and function gradually remodeled and declined with**
 25 **age.**

26 ● **SARS-CoV-2-specific immunity declined with age in fatal cases.**

27 ● **SARS-CoV-2-specific immunity was associated with survival time in fatal**
 28 **cases.**

29 ● **Loss in the expansion of SARS-CoV-2-specific immunity could be expanded**
 30 ***in vitro*.**

31 ● **A concurrent decline in SARS-CoV-2-specific cellular and humoral**
 32 **immunities and prolonged SARS-CoV-2 exposure predicted fatal outcomes.**

33

34

35

36

37

38

39

40

41

42 **Keywords**

43 CD4; CD8; COVID-19; Expansion; IFN γ ; SARS-CoV-2 specific immunity; SARS-CoV-2; T cells

44 ABSTRACT

45 Knowledge of the dynamic immunological characteristics of patients with coronavirus
 46 disease 2019 (COVID-19) is essential for clinicians to understand the progression of
 47 the disease. Our data showed that the immune system and function gradually
 48 remodeled and declined with age, starting from age 16 until age 91 in 25,239 healthy
 49 controls. An analysis of the relationship between the number of lymphocytes and age
 50 revealed that the lymphocyte and subset counts tended to decline with age
 51 significantly. Severe acute respiratory syndrome coronavirus 2
 52 (SARS-CoV-2)-specific immunity declined with age and was associated with survival
 53 time in fatal cases. Loss in the expansion of SARS-CoV-2-specific immunity could be
 54 expanded *in vitro*. The concurrent decline in SARS-CoV-2-specific cellular and
 55 humoral immunities and prolonged SARS-CoV-2 exposure predicted fatal outcomes.
 56 Our findings provide a basis for further analysis of SARS-CoV-2-specific immunity
 57 and understanding of the pathogenesis of fatal COVID-19 cases.

58

59

60

61

62

63

64

65

66 INTRODUCTION

67 Coronavirus disease 2019 (COVID-19) pandemic leads to severe illness, life-threatening
68 complications, and death, especially in high-risk groups such as elderly people and individuals
69 with comorbidities¹⁻⁷. However, information on immunological characteristics in the assessment
70 of COVID-19 for frontline clinicians is limited. The objective of this study is to explore the
71 dynamic immunological characteristics as the disease progresses.

72 In January, 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was
73 identified in samples of bronchoalveolar lavage fluid from patients in Wuhan, China, and was
74 confirmed as the cause of the SARS-CoV-2 pneumonia^{1,2}. Full-genome sequencing and
75 phylogenic analysis indicated that SARS-CoV-2 is a distinct clade from the betacoronaviruses
76 associated with human SARS and Middle East respiratory syndrome (MERS)^{1,2}.

77

78 COVID-19 has spread rapidly since it was first identified in Wuhan and has been shown to have a
79 wide spectrum of severity. Recently, a report shows that SARS-CoV and SARS-CoV-2 shared the
80 same functional host-cell receptor, angiotensin-converting enzyme 2 (ACE2)⁸. Furthermore,
81 SARS-CoV-2 binds to ACE2 receptors in 10-20 fold higher affinity than SARS-CoV binds to the
82 same receptors⁸. The receptor binding domain is recognized by the extracellular peptidase domain
83 of ACE2 mainly through polar residues, which provide important insights into the molecular basis
84 for coronavirus recognition and infection⁹. Since ACE2 receptors on lung alveolar epithelial cells
85 and enterocytes of the small intestine are highly expressed, lung alveolar epithelial cells or
86 enterocytes of the small intestine may be an important source of infection¹⁰.

87 According to World Health Organization (WHO) interim guidance on January 12, 2020,
88 SARS-CoV-2 infection is classified as asymptomatic, mild, severe, and critical cases of
89 pneumonia (acute respiratory distress syndrome [ARDS], sepsis, septic shock). Severe cases of
90 pneumonia are defined as patients with respiratory rate > 30 breaths/min, severe respiratory
91 distress, or peripheral capillary oxygen saturation < 90% on room air¹¹. Asymptomatic cases have
92 been reported in China and Germany^{12,13}. Huang et al.² first reported 41 cases of SARS-CoV-2
93 pneumonia in which most patients had a history of exposure to Huanan Seafood Wholesale
94 Market. Organ dysfunction (shock, ARDS, acute cardiac injury, and acute kidney injury, etc.) and
95 death can occur in severe or critical cases. Guan et al.³ reported findings from 1,099 cases of
96 SARS-CoV-2 pneumonia and the results suggested that the SARS-CoV-2 infection clustered
97 within groups of people in close contact, and was more likely to affect the old with comorbidities.
98 However, there is no pre-existing antibody-mediated immunity to SARS-CoV-2 at the population
99 level, leading to more than half million deaths and 10 millions of infections which have been
100 reported worldwide as of June 29, 2020¹⁴.

101 The disease severity is associated with immune dysregulation, for example, dysregulation of T
102 cells, or associated with macrophage activation syndrome¹⁵⁻²¹. Grifoni et al.²² reported
103 SARS-CoV-2-specific CD4 and CD8 T cells responses in 20 recovery cases of COVID-19. Using
104 multiple experimental approaches, SARS-CoV-2-specific CD4 T cell and antibody responses were
105 observed in all COVID-19 patients and SARS-CoV-2-specific CD8 T cell responses were seen in
106 most COVID-19 patients. All of the patients had SARS-CoV-2-specific CD4 T cells that
107 recognized the virus's spike protein, and 70% of them had SARS-CoV-2-specific CD8 T cells that
108 responded to the same protein. The identification of strong T cell responses in recovered

COVID-19 patients promotes further study in designing vaccines to induce T cell responses. Ni et al.¹⁸ also observed SARS-CoV-2-specific humoral and cellular immunity in 14 convalescent patients. However, to the best of our knowledge, SARS-CoV-2-specific CD4 and CD8 T cell responses in fatal cases of COVID-19 were not reported. Furthermore, understanding the key immune mechanisms to recover from novel SARS-CoV-2 exposure is an urgent need.

It is important to understand the key risk factors of critical patients who died. We hypothesize that lethal COVID-19 disease would be associated with immune dysregulation and loss expansion of SARS-CoV-2-specific immunity. Here, we analyzed dynamic immunological characteristics in fatal COVID-19 patients in a unique longitudinal cohort of samples.

RESULTS

The immune system and function gradually remodeled and declined with age in 25,239 healthy controls.

The numbers of lymphocytes and subset counts, except for natural killer (NK) cells, tended to decline with age significantly (Spearman $R = -$ [range, 0.9048–1], $P < 0.001$, Figure 1A–E and Table S2). However, the relationship between the number of NK cells and age only showed a tendency of the NK cells to increase in number with age (Spearman $R = 0.6429$, $P = 0.0962$, Figure 1F and Table S2).

SARS-CoV-2-specific immunity declined with age in fatal COVID-19 cases

The SARS-CoV-2-specific immunity tended to decline with age (Figure 2A–C).

130 However, the virus load tended to increase with age (Figure 2D).

131 The ability to expand SARS-CoV-2-specific interferon gamma (IFN γ)+CD4+ T cells
 132 (Spearman $R = -0.8020$, $P < 0.0001$, Figure 2A) and IFN γ +CD8+ T cells (Spearman R
 133 $= -0.8028$, $P < 0.0001$, Figure 2B) was significantly inversely related to age. This
 134 suggests that the elderly had low expansion ability of SARS-CoV-2-specific T-cell
 135 immunity, which led to the faster progression of the disease to a severe illness, an
 136 important risk factor of mortality in the elderly. SARS-CoV-2-specific humoral
 137 immunity (Spearman $R = -0.2671$, $P = 0.0254$, Figure 2C) was also inversely related
 138 to age. However, this relationship was weaker than that of SARS-CoV-2-specific
 139 T-cell immunity with age. The SARS-CoV-2 viral load was directly and significantly
 140 proportional to age (Spearman $R = 0.4780$, $P < 0.0001$, Figure 2D). This suggests that
 141 the elderly easily contracted the infection or that the patients had a higher viral load in
 142 the body.

143 **SARS-CoV-2-specific immunity is associated with survival time in fatal** 144 **COVID-19 cases**

145 As the survival time increased, the SARS-CoV-2-specific immunity tended to increase.
 146 However, the relationship between virus load and survival time showed that the virus
 147 load tended to decrease as the survival time increased (Figure 3).

148

149 The correlations between SARS-CoV-2-specific IFN γ +CD4+ T cells (Spearman $R =$
 150 0.7655 , $P < 0.0001$, Figure 3A) and IFN γ +CD8+ T cells (Spearman $R = 0.7623$, $P <$

0.0001, Figure 3B) and survival time were relatively strong and significant, suggesting that the patient's survival time depended on the expansion ability of SARS-CoV-2-specific T-cell immunity. The aggregated data for 4 weeks showed that SARS-CoV-2-specific humoral immunity was significantly related to survival time (Spearman $R = 0.7924$, $P < 0.0001$, Figure 3C). The SARS-CoV-2 viral load was inversely proportional to survival time (Spearman $R = -0.4730$, $P < 0.0001$, Figure 3D). This suggests that the higher the viral load of SARS-CoV-2, the shorter the survival time of the patient. Therefore, controlling the replication of the virus might prolong the survival time of patients.

160

We found no significant difference in the frequency of SARS-CoV-2-specific IFN γ +CD4 $^{+}$ T cells (Figure 4A) between the first and second weeks. However, significant differences were observed between the first and third or fourth weeks, possibly indicating that SARS-CoV-2-specific IFN γ +CD4 $^{+}$ T cells began to expand in the third week significantly (Figure 4A). No significant difference in the frequency of SARS-CoV-2 specific IFN γ +CD8 $^{+}$ T cells was found between the first and second, third, or fourth weeks, indicating that the expansion of the specific CD8 T cells was lost (Figure 4B). A significant difference in the titer of the specific IgG antibodies was found between the first and second weeks. Compared with that at week 1, the IgG titer in weeks 2–4 continued to show significant differences, which suggests that the SARS-CoV-2-specific antibodies began to expand in the second week, but the antibody titer was low (Figure 4C). Significant differences were found between the

173 viral loads from weeks 1 to 4 (Figure 4D), indicating that the SARS-CoV-2-specific
174 immunity could potentially clear the SARS-CoV-2 replication in fatal cases. However,
175 the SARS-CoV-2-specific immunity was unable to clear all SARS-CoV-2 replications
176 in the fatal cases. The mean viral load was 6.7×10^4 copies/mL at week 3, indicating
177 the presence of persistent SARS-CoV-2 infection.

178

179 **The loss in the expansion of SARS-CoV-2-specific immunity in the fatal cases**
180 **could be expanded *in vitro***

181 From our results, we can infer that the key factor was loss in the expansion of
182 SARS-CoV-2-specific humoral and cellular immunities, causing the virus to remain in
183 the body in fatal cases. As the expansion of SARS-CoV-2-specific immunity started
184 from the first 2–3 weeks, we chose peripheral blood mononuclear cells (PMBCs) in
185 the third week for the expansion experiment *in vitro*. Our data showed that these
186 PMBCs could be expanded *in vitro*. After the expansion, SARS-CoV-2-specific
187 IFN γ +CD4 $^+$ T cells and IFN γ +CD8 $^+$ T cells increased significantly (Figure 5). This
188 suggests that the SARS-CoV-2-specific immunity lost its expansion in the 21 fatal
189 cases at week 3, but the expansion of the SARS-CoV-2-specific cellular immunity
190 was recovered in the *in vitro* experiment (Figure 5).

191

192 **A concurrent decline in SARS-CoV-2-specific cellular and humoral immunities**
193 **and prolonged SARS-CoV-2 exposure predicted fatal outcomes**

194

195 Significant correlations were observed between SARS-CoV-2-specific IFN γ +CD4 $^{+}$ T
196 cells (Spearman $R = 0.4537$, $P < 0.0001$, Figure 6A) and IFN γ +CD8 $^{+}$ T cells
197 (Spearman $R = 0.3721$, $P = 0.0002$, Figure 6B) and SARS-CoV-2-specific humoral
198 immunity.

199

200 SARS-CoV-2-specific IFN γ +CD4 $^{+}$ T cells (Spearman $R = -0.4784$, $P < 0.0001$,
201 Figure 7A) and IFN γ +CD8 $^{+}$ T cells (Spearman $R = -0.4609$, $P < 0.0001$, Figure 7B)
202 inversely correlated significantly with the SARS-CoV-2 viral load, which suggests
203 that the SARS-CoV-2-specific T-cell immunity plays a leading role in viral clearance.

204

205 SARS-CoV-2-specific humoral immunity inversely correlated significantly with
206 SARS-CoV-2 viral load, which suggests that SARS-CoV-2-specific humoral
207 immunity played a role in viral clearance (Figure 8). However, the R value of
208 SARS-CoV-2-specific humoral immunity was smaller than that of
209 SARS-CoV-2-specific T-cell immunity (Figures 7 and 8), which suggests that
210 SARS-CoV-2-specific T-cell immunity might play a major role in viral clearance in
211 fatal cases.

212

213 However, the proportion of patients with SARS-CoV-2-specific T cells was
214 significantly lower than that of COVID-19 survivors (Figure 9A, 9B), which suggests
215 a loss in the expansion of the SARS-CoV-2-specific cellular immunity in fatal cases.

216 In addition, the IgG titer was significantly lower than that in COVID-19 survivors

(Figure 9C), which suggests a loss in the expansion of SARS-CoV-2-specific humoral immunity in the fatal cases. Here, we define "loss in the expansion" as a decrease in SARS-CoV-2-specific immunity in fatal cases compared to survivors of critical COVID-19 cases.

Furthermore, SARS-CoV-2-specific immunity was unable to clear the SARS-CoV-2 replications in the fatal cases. All the patients had a positive viral load before death, which suggests that prolonged SARS-CoV-2 exposure can predict fatal outcomes (Figure 4D).

DISCUSSION

The extent of lymphopenia in patients admitted to the intensive care unit correlates with COVID-19 severity and mortality²³⁻²⁶. Therefore, studies of the immune system and function in healthy controls are important to understand whether the immune system and function is related to age. Our data showed that the immune system and function have gradually remodeled and declined with age in 25,239 healthy controls.

Channappanavar et al.²⁷ reported that SARS-CoV-specific memory CD8 T cells persisted for up to 6 years after SARS-CoV infection. When challenge with a lethal dose of SARS-CoV, virus-specific memory CD8 T cells efficiently produced IFN γ , tumor necrosis factor α (TNF- α), etc. and reduced lung viral load. Next, we tried to understand whether SARS-CoV-2-specific immunity is associated with age in those

239 fatal patients with COVID-19. Our data suggested that SARS-CoV-2-specific
240 immunity has declined with age in COVID-19 patients.

241 Levels of lymphocytes and lymphocyte subsets are of great importance to keep the
242 immune system working. Usually viral infection, immunodeficiency diseases, and
243 other infectious diseases lead to abnormal changes in the levels of lymphocyte
244 subsets¹⁶. Although SARS-CoV-2 has been identified as the causative agent of
245 COVID-19, the mechanism by which SARS-CoV-2 impacts the human immune
246 system is still unclear¹⁶.

247 Grifoni et al.²² reported SARS-CoV-2-specific CD4 and CD8 T cells responses in 20
248 recovery cases of COVID-19. SARS-CoV-2-specific CD4 T cell and antibody
249 responses were observed in all COVID-19 patients and SARS-CoV-2-specific CD8 T
250 cell responses were seen in most COVID-19 patients. Ni et al.¹⁸ also observed
251 SARS-CoV-2-specific humoral and cellular immunity in 14 convalescent patients. We
252 explored whether SARS-CoV-2-specific immunity is associated with survival time in
253 those fatal patients with COVID-19. Our data showed that SARS-CoV-2 specific
254 immunity was associated with survival time in COVID-19 patients. Our results were
255 consistent with previous reports^{18,22}.

256

257 From the above results, it can be known that the key factor was loss in the expansion
258 of SARS-CoV-2-specific humoral and cellular immunity and the virus cannot be
259 eliminated from the body in fatal cases. We tried to understand whether loss in the

260 expansion of SARS-CoV-2-specific immunity in fatal cases could be expanded *in*
 261 *vitro*. Since the expansion of SARS-CoV-2-specific immunity started from the first
 262 2-3 weeks, we chose PMBCs in the third week for the expansion experiment *in vitro*.
 263 Our data showed that these PBMCs could be expanded *in vitro*. After the expansion,
 264 SARS-CoV-2-specific IFN γ +CD4⁺ T cells and IFN γ +CD8⁺ T cells increased
 265 significantly. It suggested that the SARS-CoV-2-specific immunity of these fatal
 266 patients lost their expansion, but the expansion of SARS-CoV-2-specific cellular
 267 immunity could be recovered *in vitro* experiment.

268

269 Our data indicated that a concurrent decline in SARS-CoV-2 specific cellular and
 270 humoral immunity and prolonged SARS-CoV-2 exposure predicted fatal outcomes.
 271 First, the immune system and function have gradually remodeled and declined with
 272 age in healthy controls. Therefore, the elderly are susceptible to the SARS-CoV-2.
 273 Second, our data showed that SARS-CoV-2-specific immunity has declined with age
 274 in COVID-19 patients. Therefore, the elderly easily turned from mild to severe
 275 SARS-CoV-2 infections. Those results have explained that the elderly is a risk factor
 276 for poor outcomes. Third, our data further showed that SARS-CoV-2-specific
 277 immunity is associated with survival time in COVID-19 patients. The correlation
 278 between SARS-CoV-2-specific IFN γ +CD4⁺ T cells and IFN γ +CD8⁺ T cells and
 279 survival time was relatively strong, and significantly correlated with survival time,
 280 suggesting that patient survival time depended on the expansion ability of
 281 SARS-CoV-2-specific T cell immunity. The aggregated data for 4 weeks showed that

282 SARS-CoV-2-specific humoral immunity was related to survival time. SARS-CoV-2
283 viral load was inversely proportional to survival time significantly. It suggested that
284 the higher the viral load of SARS-CoV-2, the shorter the survival time of patients.
285 Therefore, controlling the replication of the virus might prolong the survival time of
286 patients. Finally, we observed that a concurrent decline in SARS-CoV-2-specific
287 cellular and humoral immunity and prolonged SARS-CoV-2 exposure predicted fatal
288 outcomes. There was significant correlation between SARS-CoV-2-specific T cell
289 immunity and SARS-CoV-2-specific humoral immunity. The frequency of
290 SARS-CoV-2-specific T cells and titer of IgG were much lower than that of survivors
291 of critical COVID-19 cases and there were higher viral load in the course of the
292 disease, indicating that the persistent SARS-CoV-2 infection and loss in the expansion
293 of SARS-CoV-2-specific immunity are important factors.

294

295

296

297

298

299

300

301

302

303

304 **Acknowledgments**

305 The work was supported in part by the National Natural Science Foundation of China (Grant No.
306 81830052 and 81530053).

307 **Author contributions**

308 [#]Drs. Q Zeng, G Huang and YZ Li contributed equally to this article and share first authorship.

309 ^{*} Correspondence to Dr. Y Xu.

310

311 Q Zeng, G Huang and YZ Li contributed to study design, data interpretation, and manuscript
312 drafting. GX, ZTC, ZTC contributed to data analysis, figure preparation, the literature search, and
313 manuscript drafting. SYD and GX contributed to performed experiments, data collection, data
314 analysis, and figure preparation. YX contributed to study design and reviewed the final draft. All
315 authors read and approved the manuscript.

316

317 **Competing interests statement**

318 We declare no competing interests.

319

320

321

322

323

324

325

326 **References**

- 327 1. Zhu, N., *et al.* A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl.J.*
328 *Med.* **382**, 727-733 (2020).
- 329 2. Huang, C., *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
330 China. *Lancet (London, England)* **395**, 497-506 (2020).
- 331 3. Guan, W.J., *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N. Engl.J.*
332 *Med.* **382**, 1708-1720 (2020).
- 333 4. Li, Q., *et al.* Early transmission dynamics in Wuhan, China, of novel coronavirus-infected
334 pneumonia. *N. Engl.J. Med.* **382**, 1199-1207 (2020).
- 335 5. Wang, D., *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel
336 coronavirus-infected pneumonia in Wuhan, China. *JAMA* **323**, 1061-1069 (2020).
- 337 6. Zhou, F., *et al.* Clinical course and risk factors for mortality of adult in patients with
338 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)* **395**,
339 1054-1062 (2020).
- 340 7. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome
341 and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA*
342 *Intern Med.* **180**, 934-943 (2020).
- 343 8. Wrapp, D., *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
344 *Science (New York, N.Y.)* **367**, 1260-1263 (2020).
- 345 9. Yan, R., *et al.* Structural basis for the recognition of SARS-CoV-2 by full-length human
346 ACE2. *Science (New York, N.Y.)* **367**, 1444-1448 (2020).
- 347 10. Hamming, I., *et al.* Tissue distribution of ACE2 protein, the functional receptor for SARS

- 348 coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* **203**, 631-637
- 349 (2004).
- 350 11. World Health Organization. Clinical management of severe acute respiratory infection when
- 351 novel coronavirus (nCoV) infection is suspected. *Interim guidance on January 12, 2020*
- 352 (*accessed February 15*), <https://apps.who.int/iris/handle/10665/330854> (2020).
- 353 12. Pan, X., *et al.* Asymptomatic cases in a family cluster with SARS-CoV-2 infection. *Lancet*
- 354 *Infect. Dis.* **20**, 410-411 (2020).
- 355 13. Rothe, C., *et al.* Transmission of 2019-nCoV infection from an asymptomatic contact in
- 356 Germany. *N. Engl.J. Med.* **382**, 970-971 (2020).
- 357 14. WHO. Rolling updates on coronavirus disease (COVID-19). .
- 358 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (*accessed June 29, 2020*)
- 359 (2020).
- 360 15. Xu, Z., *et al.* Pathological findings of COVID-19 associated with acute respiratory distress
- 361 syndrome. *Lancet Respir. Med.* **8**, 420-422 (2020).
- 362 16. Vabret, N., *et al.* Immunology of COVID-19: Current State of the Science. *Immunity* **52**,
- 363 910-941 (2020).
- 364 17. Diao, B., *et al.* Reduction and functional exhaustion of T cells in patients with coronavirus
- 365 disease 2019 (COVID-19). *Front. Immunol.* **11**, 827 (2020).
- 366 18. Ni, L., *et al.* Detection of SARS-CoV-2-specific humoral and cellular immunity in
- 367 COVID-19 convalescent individuals. *Immunity* **52**, 971-977.e973 (2020).
- 368 19. Giamarellos-Bourboulis, E.J., *et al.* Complex immune dysregulation in COVID-19 patients
- 369 with severe respiratory failure. *Cell Host Microbe* **27**, 992-1000.e1003 (2020).

- 370 20. Day, C.L., *et al.* PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion
371 and disease progression. *Nature* **443**, 350-354 (2006).
- 372 21. Trautmann, L., *et al.* Upregulation of PD-1 expression on HIV-specific CD8⁺ T cells leads to
373 reversible immune dysfunction. *Nat. Med.* **12**, 1198-1202 (2006).
- 374 22. Grifoni, A., *et al.* Targets of T cell responses to SARS-CoV-2 coronavirus in humans with
375 COVID-19 disease and unexposed individuals. *Cell* **181**, 1489-1501.e1415 (2020).
- 376 23. Chen, G., *et al.* Clinical and immunological features of severe and moderate coronavirus
377 disease 2019. *J. Clin. Invest.* **130**, 2620-2629 (2020).
- 378 24. Liu, J., *et al.* Longitudinal characteristics of lymphocyte responses and cytokine profiles in
379 the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* **55**, 102763 (2020).
- 380 25. Tan, L., *et al.* Lymphopenia predicts disease severity of COVID-19: a descriptive and
381 predictive study. *Signal. Transduct. Target. Ther.* **5**, 33 (2020).
- 382 26. Wang, F., *et al.* Characteristics of peripheral lymphocyte subset alteration in COVID-19
383 pneumonia. *J. Infect. Dis.* **221**, 1762-1769 (2020).
- 384 27. Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D.K. & Perlman, S. Virus-specific
385 memory CD8 T cells provide substantial protection from lethal severe acute respiratory
386 syndrome coronavirus infection. *J. Virol.* **88**, 11034-11044 (2014).

387

388

389

390

391

392 **Figures and Legends**

393

394 **Figure 1. Dynamic distribution of lymphocytes and subsets according to age**
 395 **among the 25,239 healthy controls.** We enrolled laboratory data from 25,239 health
 396 controls in November 2017 and November 2019 from health check up before
 397 the COVID-19 pandemic.

398

399 **Figure 2. Dynamic distribution of severe acute respiratory syndrome coronavirus**
 400 **2 (SARS-CoV-2)-specific immunity and viral load according to age among the**
 401 **fatal cases.**

402

403 **Figure 3. Dynamic distribution of severe acute respiratory syndrome**
 404 **coronavirus2 (SARS-CoV-2)-specific immunity and viral load according to**
 405 **survival time among the fatal cases.**

406

407 **Figure 4. Dynamic characteristics of severe acute respiratory syndrome**
 408 **coronavirus 2 (SARS-CoV-2)-specific immunity and viral load in the fatal cases.**

409 ns, $P > 0.05$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

410

411 **Figure 5. Peripheral blood mononuclear cells (PBMCs) of the 21 fatal cases at**
 412 **week 3 stimulated with severe acute respiratory syndromecoronavirus2**
 413 **(SARS-CoV-2) spike glycoprotein peptide pools (SPs).** The graph showed the

percentage of SARS-CoV-2 specific IFN γ +CD4+T cells (A) and SARS-CoV-2 specific IFN γ +CD8+ T cells (B) reactive to the SPs directly *ex vivo* (w/o expansion) and after *in vitro* expansion (expansion). **, $P=0.0017$; ****, $P<0.0001$.

Figure 6. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T-cell immunity (interferon [IFN] γ +CD8+ and IFN γ +CD4+) showing no correlation with SARS-CoV-2-specific humoral immunity.

Figure 7. Inverse correlation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T-cell immunity (interferon [IFN] γ +CD8+ and IFN γ +CD4+) with SARS-CoV-2 viral load.

Figure 8. Inverse correlation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immunity (IgG) with SARS-CoV-2 viral load.

Figure 9. Comparison of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immunity at week 3 between the 21 fatal cases and 18 survival cases of critical COVID-19. The graph showed the percentage of SARS-CoV-2 specific IFN γ +CD4+T cells (A), SARS-CoV-2 specific IFN γ +CD8+ T cells (B) and IgG titers (C). ****, $P < 0.0001$.

436

Figure 1

437

438

Figure 2

439

Figure 3

440

Figure 4

441

442

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465 **Supplemental Materials**

466

467 **Table S1. Demographic characteristics of 35 fatal patients with COVID-19 on admission**

Characteristics	Patients
Age, Median (IRQ), years	64.0 (45.0-73.0)
Gender	
Male	24 (68.6%)
Female	11 (31.4%)
Comorbidities	
Hypertension	11 (31.4%)
Cardiovascular diseases	7 (20.0%)
Diabetes	6 (17.1%)
Main symptoms	
Fever	30 (85.7%)
Cough	18 (51.4%)
Fatigue	6 (17.1%)

468

469

470 **Table S2. Spearman's correlation test and mean of lymphocyte subsets in 25,239**
471 **healthy controls**

472

Age	CD3 ⁺	CD4 ⁺	CD8 ⁺	CD4 ⁺ /CD8 ⁺	CD19 ⁺	CD16 ⁺ CD56 ⁺
year	cells/mm ³	cells/mm ³	cells/mm ³	ratio	cells/mm ³	cells/mm ³
16-19	1835	857	621	1.24	304	257
20-29	1648	876	594	1.49	279	180
30-39	1502	852	526	1.64	247	188
40-49	1417	829	465	1.81	238	189
50-59	1379	822	428	1.92	237	200
60-69	1309	763	421	1.84	230	244
70-79	1220	718	391	1.82	210	265
80-91	938	530	348	2.09	166	304
R	-1	-0.9762	-1	0.9048	-1	0.6429
P	<0.0001	0.0004	<0.0001	0.0046	<0.0001	0.0962

473

Figure S1. A representative flow cytometry gating strategy.

489 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

490 **Study Design and Participants**

491 This retrospective study was conducted at Chinese PLA General Hospital, Peking Union Medical
492 College Hospital, the First Affiliated Hospital, and affiliated hospitals of Shanghai University of
493 Medicine and Health Sciences. Chinese PLA General Hospital and Peking Union Medical College
494 Hospital are the largest clinical research hospitals in China. Demographic characteristics of 35
495 fatal patients with COVID-19 on admission were listed in Table S1. The 18 critical cases (matched
496 by age and sex) who survived were enrolled for comparison. This case series was approved by the
497 institutional ethics board of Chinese PLA General Hospital (#2020-111), Peking Union Medical
498 College Hospital (#ZS-1830), The First Affiliated Hospital (#KY2020046), and Shanghai
499 University of Medicine and Health Sciences (#2019-LCHZ-18-20190507). Written informed
500 consent was obtained from healthy controls and waived to COVID-19 patients due to the rapid
501 emergence of this infectious disease. Identification of hypertensive patients was achieved by
502 reviewing and analyzing available electronic medical records and patient care resources. Clinical
503 outcomes (discharge, mortality, and recovery, etc.) were monitored and all clinical recovery
504 hypertensive patients meet the following criteria: body temperature returned to normal for more
505 than 3 days, respiratory symptoms improved significantly, and lung imaging showed significant
506 improvement.

507

508 **METHOD DETAILS**

509 **Cell preparation**

510 Whole blood was centrifuged for 15 min at 1800 rpm to separate the cellular fraction and plasma.

511 The plasma was then carefully removed from the cell pellet and stored at -20°C. Peripheral blood
512 mononuclear cells (PBMCs) were isolated using Ficoll-Paque PLUS density gradients (GE
513 Healthcare Life Sciences, USA) according to the manufacturer's instructions. Isolated PBMCs
514 were either studied directly or cryopreserved in cell recovery media containing 10% DMSO
515 (Gibco, USA), supplemented with 10% heat inactivated fetal bovine serum and stored in liquid
516 nitrogen until used in the assays. Cryopreserved PBMCs were thawed by diluting them in 10 mL
517 complete RPMI 1640 with 5% human AB serum (Gemini Bioproducts, USA) in the presence of
518 benzonase (final concentration at 50 U/mL) before an experiment.

519 **SARS-CoV-2 Spike glycoprotein peptide pools**

520 SARS-CoV-2 Spike glycoprotein peptide pools (SPs) were from Genscript Biotech, USA. SPs
521 include 316 peptides (delivered in two subpools of 158 peptides) derived from a peptide scan (15
522 mers with 11 amino acid overlap) through the entire Spike glycoprotein of SARS-CoV-2.

523 **Expansion of PBMCs *in vitro***

524 20% of PBMCs were pulsed with 10 µg/mL of the SPs for 1 hour at 37 °C, subsequently washed,
525 and cocultured with the remaining cells in AIM-V medium (Gibco; Thermo Fisher Scientific,
526 USA) supplemented with 2% AB human serum (Gibco; Thermo Fisher Scientific, USA). PBMCs
527 were cultured for 7 days in the presence of 20 U/mL of recombinant IL-2 (R&D Systems, USA).

528 **Intracellular cytokine staining (ICS) assay**

529 PBMCs were first stimulated with or without SPs (2 µg /mL) for 3 h at 37°C, then brefeldin A (10
530 µg/mL, Sigma-Aldrich, USA) was added to cultures to enable intracellular proteins to accumulate
531 in all stimulations. PBMCs were stimulated RPMI medium containing 10% FCS as a negative
532 control. After incubation for a total of 6 h, the cells were washed, fixed, permeabilized using

533 fixation/permeabilization solution kit (BD Biosciences, USA) and blocked with FcR blocking
534 reagent (Molten Biochemical, USA) for 30 min at 4 °C to reduce nonspecific binding of antibodies to
535 human Fc receptor. The cells were then stained with anti-IFN γ antibodies (BD Bioscience, USA)
536 for 30 min at 4 °C. After staining, all samples were washed twice with phosphate buffered saline
537 (PBS) containing 0.1% saponin, 0.1% BSA and 0.05% NaN₃ (Sigma-Aldrich, USA), and
538 resuspended in 300 μ L PBS for measurement in a flow cytometer (FACSVerse™ flow cytometry,
539 BD Bioscience, USA).

540 **Real-time reverse transcription polymerase chain reaction (RT-PCR) assay for SARS-CoV-2**

541 Throat, sputum and blood samples were collected for extracting SARS-CoV-2 RNA from
542 hypertensive patients suspected of having SARS-CoV-2 infection. In brief, RNA was extracted
543 within 2 h using the total RNA isolation kit. Cell lysates (250 μ L) were transferred into a
544 collection tube followed by vortex for 10 s. After standing at room temperature for 10 min, the
545 collection tube was centrifuged at 1000 rpm for 5 min. The suspension was used for RT-PCR
546 assay of SARS-CoV-2 RNA. Two target genes, including open reading frame 1ab (ORF1ab) and
547 nucleocapsid protein (N), were simultaneously amplified and tested during the RT-PCR assay.
548 The sequences of primers and probes were: Target 1 (ORF1ab): forward primer
549 CCCTGTGGGTTTTACTTAA; reverse primer ACGATTGTGCATCAGCTGA; and the probe
550 5'-VIC-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'. Target 2 (N): forward primer
551 GGGGAACCTCTCCTGCTAGAAT; reverse primer CAGACATTTTGCTCTCAAGCTG; and
552 the probe 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'. The RT-PCR assay was
553 performed using a SARS-CoV-2 nucleic acid detection kit. Reaction mixture contained 12 μ L of
554 reaction buffer, 4 μ L of enzyme solution, 4 μ L of probe primer solution, 3 μ L of diethyl

pyrocarbonate-treated water, and 2 μ L of RNA template. The RT-PCR assay was performed under the following conditions: incubation at 50 °C for 15 min and 95 °C for 5 min, 40 cycles of denaturation at 94 °C for 15 s, and extending and collecting fluorescence signal at 55 °C for 45 s. A cycle threshold value (C_t -value) less than 37 was defined as a positive test result, and a C_t -value of 40 or more was defined as a negative test. These diagnostic criteria were based on the recommendation by the National Institute for Viral Disease Control and Prevention (China). Samples with a C_t -value of 37 to less than 40 was confirmation by retesting. The copies of RNA per reaction were obtained from the standard curve of limiting-dilution series of standard copies of RNA versus PCR amplification cycle.

Enzyme-linked immunosorbent assay (ELISA) of immunoglobulin (Ig)

Antibodies (IgM, IgA, and IgG) specific to SARS-CoV-2 were determined with two different ELISA: an in-house assay using SARS-CoV-2 Receptor Binding Domain (RBD) protein (Cat. #Z03479, Genscript Biotech, USA) as an antigen, or a commercial kit (SARS-CoV-2 Spike RBD ELISA Kit, Cat. #40591-V08H, Sino Biological, China). Microtiter plates were coated with 50 ng/well of target protein overnight at 4 °C. Plates were then blocked for 2 h at 37 °C using 200 μ L of 5% non-fat milk in PBS. Serum samples were then diluted into 1:50 using PBS and 100 μ L of each sample was applied to coated ELISA plate and incubated for 2 h at 37 °C. Plates were then washed with PBS and incubated with HRP-labeled anti-human IgM, IgA, and IgG (Sigma Aldrich, USA), which were diluted to 1:2000 in 5% non-fat milk in PBS. After incubation for another 1 h at room temperature, the plates were washed and developed with TMB/E substrate (Millipore, USA). Finally, the reaction was stopped with 1 M H_2SO_4 , and the optical density (OD) at 450 nm was measured. Negative serum control was run each time when the assay was performed. A

sample is positive if its adjusted OD value (OD of test – OD of control) exceeds the mean plus 3 standard deviations of the normal controls.

Flow cytometry analysis

All samples were analyzed by FACSVerse™ flow cytometry (BD Bioscience, USA). Two blood samples in two tubes (100 µL each) were stained according to the manufacturer's instructions. Then, red-cell lysis buffer (1 mL) was added to each tube, the samples were incubated for 10 min and washed with Sorvall cell washer (Thermo Fisher Scientific, USA). Cells were blocked with FcR blocking reagent (Molten Biochemical, USA) for 30 min at 4 °C to reduce nonspecific binding of antibodies to human Fc receptor and washed with PBS. The cells were then stained with antibodies as listed in Figure and the fixable dead cell stain kit (Invitrogen, USA) for 30 min at 4 °C and were then resuspended in 350 µL PBS and analyzed in flow cytometry (FACSVerse™ flow cytometry, BD Bioscience, USA). Calibration and quality control for the instrument were carried out daily with the use of eight-color setup beads (BD Bioscience). All specimens were analyzed in duplicates with coefficient of variation (CV) < 5% by two independent technicians under the inter-laboratory quality control. The experiments were repeated if the results showed CV > 5% according to the instructions of BD Bioscience. The data were analyzed by FlowJo software (version 10, Tree Star, USA).

Statistical analysis

Categorical variables were described as frequency rates and percentages, and continuous variables were described using mean and median values. Means for continuous variables were compared using independent group *t* tests when the data were normally distributed; otherwise, the Mann-Whitney test was used. Data (non-normal distribution) from repeated measures were

599 compared using the generalized linear mixed model. Proportions for categorical variables were
600 compared using the χ^2 test, although the Fisher's exact test was used when the data were limited.
601 All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences
602 Inc., version 13.0). For unadjusted comparisons, a two-sided P value less than 0.05 was
603 considered statistically significant. The analyses have not been adjusted for multiple comparisons
604 and, given the potential for type I error, the findings should be interpreted as exploratory and
605 descriptive. Because the cohort of patients in our study was not derived from random selection, all
606 statistics are deemed to be descriptive only.

607

608